<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04430309</url>
  </required_header>
  <id_info>
    <org_study_id>202000817B0</org_study_id>
    <nct_id>NCT04430309</nct_id>
  </id_info>
  <brief_title>Baduanjin on Patients With Schizophrenia</brief_title>
  <official_title>The Feasibility and Efficacy of Baduanjin Exercise on Cognition and Physical Fitness Among Patients With Schizophrenia:Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As an ancient, popular Chinese exercise, Baduanjin is characterized by symmetrical posture,&#xD;
      deep breathing and meditation and easy to learn. Previous studies showed immediate effect of&#xD;
      Baduanjin on cognition in patients with schizophrenia.The purpose of this study is to&#xD;
      investigate the immediate effect and chronic effect of Baduanjin exercise on physical&#xD;
      fitness, cognition and daily functions in middle-aged and older adults with schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-blind, 2-arm randomized controlled trial investigating the benefits of Baduanjin&#xD;
      exercise on middle-aged and older patients with schizophrenia. A total of 48 participants&#xD;
      will be assigned to either 12 weeks of 60-minute two sessions per week Baduanjin exercise&#xD;
      group or a brisk walking group. Primary outcomes are physical fitness and cognition&#xD;
      functions. Secondary outcomes are dual task performance and daily functions. Evaluation will&#xD;
      be completed at baseline, immediately after treatment and 4-week follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change scores of 6-minute walk test</measure>
    <time_frame>Baseline, immediate after treatment, 4-week follow up</time_frame>
    <description>This test evaluates cardiovascular fitness and walking speed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change scores of 30-second chair stand test</measure>
    <time_frame>Baseline, immediate after treatment, 4-week follow up</time_frame>
    <description>This test evaluates muscular endurance of lower-extremities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change scores of Timed up-and-go test</measure>
    <time_frame>Baseline, immediate after treatment, 4-week follow up</time_frame>
    <description>This test evaluates functional mobility, agility and balance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change scores of Montreal cognitive assessment</measure>
    <time_frame>Baseline, immediate after treatment, 4-week follow up</time_frame>
    <description>This test evaluates global cognition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change scores of Trail making test (part A and part B)</measure>
    <time_frame>Baseline, immediate after treatment, 4-week follow up</time_frame>
    <description>This test evaluates speed of processing, visual attention and cognitive flexibility.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change scores of Logical Memory</measure>
    <time_frame>Baseline, immediate after treatment, 4-week follow up</time_frame>
    <description>It is a subtest of the Wechsler Memory Scale. This test evaluates memory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change scores of dual task Timed up-and-go test (manual)</measure>
    <time_frame>Baseline, immediate after treatment, 4-week follow up</time_frame>
    <description>This test requires carry a cup of water 3 cm from the top of the cup while performing the Timed up-and-go test. It evaluates dual task performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change scores of dual task Timed up-and-go test (cognitive)</measure>
    <time_frame>Baseline, immediate after treatment, 4-week follow up</time_frame>
    <description>This test combine serial three counting and Timed up-and-go test simultaneously. It evaluates dual task performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change scores of Activities of Daily Living Rating Scale III</measure>
    <time_frame>Baseline, immediate after treatment, 4-week follow up</time_frame>
    <description>It is a self-administered, paper-and-pencil test that evaluates daily functions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Baduanjin exercise group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will practice Badunjin in a group which include 6-8 participants and one trained medical staff. The Baduanjin is an ancient Chinese mind-body exercise, which comprised of eight simple movements.&#xD;
The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will receive brisk walking activities. The sessions will take place twice a week, 60 minutes per session for a total duration of 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Baduanjin exercise program</intervention_name>
    <description>The sessions includes 10-minute warm-up, 40-minute Baduanjin exercise and 10-minute cool down.</description>
    <arm_group_label>Baduanjin exercise group</arm_group_label>
    <other_name>Eight Silken Movements</other_name>
    <other_name>Eight Silk Weaving</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brisk walking program</intervention_name>
    <description>The sessions includes 10-minute warm-up, 40-minute brisk walking and 10-minute cool down.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having a diagnosis of schizophrenia according to the DSM-5.&#xD;
&#xD;
          -  Independent adult aged 40 years or older in the day-care center.&#xD;
&#xD;
          -  Having a stable mental status without shift in medication and keep in same dose for at&#xD;
             least one month.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious physical conditions that will impede participation, such as cardiovascular&#xD;
             disease, musculoskeletal disease or pulmonary system disease.&#xD;
&#xD;
          -  Visual or auditory impairment that precludes completion of assessment.&#xD;
&#xD;
          -  Acute psychosis requiring hospitalization.&#xD;
&#xD;
          -  Presence of severe withdrawal or profound cognitive disability that cause difficulties&#xD;
             in following instructions.&#xD;
&#xD;
          -  Participating in another clinical trial at the same time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chyi-Rong Chen, Master</last_name>
    <phone>+886-7-7317123</phone>
    <phone_ext>8755</phone_ext>
    <email>ccr776@cgmh.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Kaohsiung Medical Center</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chyi-Rong Chen</last_name>
      <phone>+886-7-7317123</phone>
      <phone_ext>8755</phone_ext>
      <email>ccr776@cgmh.org.tw</email>
    </contact>
    <contact_backup>
      <last_name>Yee-Wen Lee</last_name>
      <phone>+886-7-7317123</phone>
      <phone_ext>8691</phone_ext>
      <email>hikare2000@cgmh.org.tw</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia, mind body intervention ,Baduanjin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

